Hangzhou Yingchuang Pharmaceutical Technology

Hangzhou Yingchuang Pharmaceutical Technology, operating as InnoCure, is a clinical-stage biotechnology company based in Hangzhou, China, dedicated to developing first-in-class and best-in-class small molecule therapeutics. Founded by industry veterans from Eli Lilly and Jiangsu Hengrui, the company focuses on challenging targets such as protein-protein interactions (PPI) and utilizes advanced modalities like Proteolysis-targeting chimeras (PROTAC). Its lead candidate, INC-1001, is a potent PARP inhibitor currently undergoing clinical evaluation for various solid tumors. InnoCure aims to address significant unmet medical needs in oncology and immunology through its robust internal R&D engine and strategic venture backing.